Leslie Norwalk Sells 1,190 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 1,190 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the completion of the sale, the director owned 6,239 shares in the company, valued at $967,606.51. This represents a 16.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences Stock Down 4.7%

Shares of NBIX traded down $7.04 during trading hours on Wednesday, reaching $141.70. 1,740,144 shares of the company traded hands, compared to its average volume of 1,152,484. The stock has a market capitalization of $14.13 billion, a PE ratio of 33.90, a price-to-earnings-growth ratio of 1.01 and a beta of 0.27. The stock has a fifty day simple moving average of $145.88 and a 200 day simple moving average of $137.74. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same quarter in the previous year, the company posted $1.81 EPS. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of large investors have recently modified their holdings of the company. Golden State Wealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. Eastern Bank acquired a new position in Neurocrine Biosciences during the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. lifted its position in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Quent Capital LLC purchased a new stake in Neurocrine Biosciences during the third quarter worth approximately $32,000. Finally, WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter worth $32,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NBIX. Mizuho upped their price objective on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Royal Bank Of Canada increased their price target on Neurocrine Biosciences from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. UBS Group raised their price objective on Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Stifel Nicolaus upped their target price on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Piper Sandler lifted their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.76.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.